Prescribing information


Xolair in key guidelines/recommendations relevant to the UK.

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1


Treatment algorithm for urticaria according to the EAACI/GA2LEN/EDF/WAO guidelines (2017)2



Not licensed for treatment in CSU.

Adapted from Zuberbier T et al. 2018.2


British Association of Dermatologists (BAD) guidelines for the evaluation and management of urticaria in adults and children (2007)3 


Not licensed for treatment in CSU.

Adapted from Grattan CE et al. 2007.3


British Society for Allergy & Clinical Immunology (BSACI) guideline for the management of chronic urticaria and angioedema (2015)4


A short course of corticosteroids may be appropriate in severe episodes at any stage (e.g. prednisolone up to 40 mg daily for 7 days).

Not licensed for treatment in CSU.

Adapted from Powell RJ et al. 2015.4


*A post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.5

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; EAACI, European Academy of Allergy and Clinical Immunology; EDF, European Dermatology Forum; GA2LEN, Global Allergy and Asthma European Network; IgE, immunoglobulin E; LTRA, leukotriene receptor antagonist; WAO, World Allergy Organization.


  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Zuberbier T et al. Allergy 2018;73(7):1393–1414.
  3. Grattan CE et al. Br J Dermatol 2007;157(6):1116–1123.
  4. Powell RJ et al. Clin Exp Allergy 2015;45(3):547–565.
  5. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
Rate this content: 
No votes yet
XSU20-C009 July 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]